Effect of 6S refined individualized nursing management in perioperative period of Parkinson's disease patients undergoing deep brain stimulation - Scorecard - MDSpire

Effect of 6S refined individualized nursing management in perioperative period of Parkinson's disease patients undergoing deep brain stimulation

  • By

  • Luo, Yunhui

  • Guo, Fang

  • Bai, Jing

  • Li, Xuan

  • Bei, Jinghua

  • Xing, Yujing

  • Zhang, Feng

  • April 28, 2026

  • 0 min

Share

Clinical Scorecard: Impact of 6S Tailored Nursing Strategies on Perioperative Outcomes in Parkinson's Disease Patients Undergoing Deep Brain Stimulation

At a Glance

CategoryDetail
Condition
Key Mechanisms6S refined individualized nursing management (source needed)
Target Population
Care Setting

Key Highlights

  • Shorter time to first ambulation in study group (13.41 vs 14.89 hours) (source needed)
  • Reduced postoperative length of stay in study group (10.34 vs 11.22 days) (source needed)
  • Lower anxiety and depression scores in study group (source needed)

Guideline-Based Recommendations

Diagnosis

    Management

      Monitoring & Follow-up

        Risks

          Patient & Prescribing Data

          6S refined individualized nursing management (source needed)

          Clinical Best Practices

            Related Resources & Content

              Original Source(s)

              Effect of 6S refined individualized nursing management in perioperative period of Parkinson's disease patients undergoing deep brain stimulation

              • by Luo, Yunhui , Guo, Fang , Bai, Jing , Li, Xuan , Bei, Jinghua , Xing, Yujing , Zhang, Feng

              • April 28, 2026

              Related Content

              Intermittent Theta-Burst Stimulation for Depressive Symptoms in Parkinson Disease: A Randomized Clinical Trial

              Balancing benefits and challenges of eHealth for family caregivers of people with Parkinson’s disease – A qualitative study

              The novel GLP-1/GIP dual receptor agonist DA5-CH is superior to tirzepatide and exendin-4 in the 6-OHDA Parkinson rat model